Ken Griffin Ikena Oncology, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 158,215 shares of IKNA stock, worth $218,336. This represents 0.0% of its overall portfolio holdings.
Number of Shares
158,215
Previous 79,687
98.55%
Holding current value
$218,336
Previous $101,000
109.9%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding IKNA
# of Institutions
45Shares Held
33.6MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.02MShares$6.93 Million1.48% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.09MShares$5.65 Million2.97% of portfolio
-
Bml Capital Management, LLC Zionsville, IN4.03MShares$5.56 Million4.09% of portfolio
-
Bvf Inc San Francisco, CA4.01MShares$5.53 Million0.21% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$4.88 Million0.17% of portfolio
About Ikena Oncology, Inc.
- Ticker IKNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,257,500
- Market Cap $50M
- Description
- Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...